Summary of Omega-3 Fatty Acids
August 19th, 2026
Commonly known as “brain food”, omega-3 fatty acids (eg, EPA/DHA) are known to be a healthy resource for the human brain as they serve as structural building blocks for neuronal membranes, act as potent anti-inflammatory agents, and upregulate brain-derived neurotrophic factor (BDNF), which is single-handedly one of the most critical proteins known to help ameliorate psychiatric illnesses across the board. Human synthesis of EPA/DHA is inefficient, so human brain levels depend heavily on dietary intake.
Fortunately, omega-3 fatty acids are readily available as an over-the-counter medication which has good evidence as an adjunct treatment for depression, anxiety, and/or vaping cessation dosed at ~2mg daily (with EPA >1g/day).
If you’d like to purchase omega-3 fatty acids, please visit the affiliate link below.
This product linked is dosed at 2g per capsule (, therefore 1 capsule (2g) daily would be sufficient per dosing guidelines.
As a disclaimer, qualified purchases will go towards to an Amazon Associate account which in turn helps to keep this website going. Thank you!
affiliate link
How do Omega-3’s help our body?
The leading theories fall into four categories: membrane/structural, neurotransmission, anti-inflammatory/pro-resolution, and neurotrophic/neuroplasticity effects.
Membrane structure and fluidity (structural theory): DHA is the predominant omega-3 in neuronal and glial cell membranes, concentrated in gray matter and synapses, earning it the label "brain food." Human synthesis (de novo) of DHA/EPA from precursors is inefficient, so human brain levels depend heavily on dietary intake. Incorporation of DHA into phospholipids increases membrane fluidity, which in turn modulates the conformation and activity of membrane-embedded proteins—such as receptors, ion channels, and membrane-bound enzymes—thereby improving the efficiency of neurotransmission.
Neurotransmission: both DHA and EPA regulate neurotransmitter release and postsynaptic receptor binding. Omega-3–deficient diets are associated with reduced receptor density and disrupted signaling in serotonergic, dopaminergic, and adrenergic systems—systems central to mood regulation.
Anti-inflammatory and pro-resolution effects (specialized pro-resolving mediators): EPA and DHA are enzymatically converted (via lipoxygenase, cyclooxygenase, and CYP450 pathways) into specialized pro-resolving lipid mediators—resolvins (E- and D-series), protectins/neuroprotectin D1, and maresins—that actively resolve inflammation, reduce oxidative stress, and promote clearance of apoptotic cells and debris. At the cellular level, omega-3s shift microglia from a pro-inflammatory (M1) toward an anti-inflammatory (M2) phenotype and suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), partly through SIRT1-mediated inhibition of NF-κB signaling. Because neuroinflammation and elevated cytokines are implicated in depression and neurodegeneration, this pathway links omega-3s to both mood and cognitive outcomes. This is arguably the most mechanistically developed theory.
Neurotrophic support and neuroplasticity: omega-3s upregulate brain-derived neurotrophic factor (BDNF) which is one of the most important proteins in the brain that helps to promote neurogenesis, synaptic plasticity, and cerebral perfusion (via vasodilation). Increased expression of BDNF is thought to be one of the most critical factors to help address psychiatric illnesses across the board. DHA also supports myelination and synaptic pruning during development, and DHA deficiency in animal models downregulates plasticity markers (Egr-1, Arc, BDNF) and produces anxiety/depression-like and memory-impairment phenotypes that are reversible with repletion.
What dose should I use for Omega-3?
A high-EPA formulation (eg, EPA ≥60% of EPA+DHA), a total dose is recommended around 1500–2000 mg/day (with ~1000mg EPA) for mood and anxiety.
Position as an adjunct—well tolerated (mainly mild GI effects, no increase in adverse events)—not a replacement for antidepressants, antipsychotics, or first-line cessation pharmacotherapy. [3][5]
Would you like to drill into the optimal EPA:DHA ratio and formulation selection for depression?
What is the evidence for Omega-3?
For initial insomnia (eg, difficulty with sleep initiation)
Evidence shows that 3-4mg is sufficient, with doses higher causing more potential for adverse effects (eg, vivid dreams, drowsiness).
A 2024 dose-response meta-analysis (26 RCTs) found efficacy for reducing sleep-onset latency and increasing total sleep time increases with dose, peaking at ~4 mg/day, with no additional benefit beyond that. It also suggested that administering melatonin around 2 hours before desired bedtime (rather than the usual 30 minutes) optimizes effect, and that response is blunted in insomnia patients relative to healthy volunteers
For comorbid/neuropsychiatric-related insomnia (eg, insomnia due to a mental illness)
An international expert panel suggested prolonged-release melatonin 2–10 mg, 1–2 hours before bedtime, with immediate-release <1 mg being better suited to circadian sleep disturbances.
What are side effects and/or precautions of Omega-3?
Melatonin is generally well tolerated with a benign side-effect profile (mild somnolence, fatigue), which is part of its appeal relative to standard hypnotics. However, individuals who have frequent nightmares (eg, PTSD-related nightmares, nightmare disorder, etc) should avoid melatonin due to a potential side effect of vivid dreams.
It is also advised to use standardized, reputable products, as over-the-counter (OTC) supplements are not FDA-regulated and may vary in purity and content.
Where can I purchase Omega-3?
If you’d like to purchase melatonin supplements, please visit the affiliate link below.
This product linked is dosed at 3mg per capsule, therefore 1 capsule (3mg) nightly 2 hours prior to sleep onset would be sufficient per dosing guidelines.
As a disclaimer, qualified purchases will go towards to an Amazon Associate account which in turn helps to keep this website going. Thank you!
affiliate link
Sources
Efficacy and Safety of N-3 Fatty Acids Supplementation on Depression: A Systematic Review and Dose-Response Meta-Analysis of Randomised Controlled Trials. The British Journal of Nutrition. 2024. Norouziasl R, Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S.
Effects of Long-Chain Omega-3 Polyunsaturated Fatty Acids on Reducing Anxiety and/or Depression in Adults; A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2023. Kelaiditis CF, Gibson EL, Dyall SC.
Management of Major Depressive Disorder (MDD) (2022). Department of Veterans Affairs. 2022. Rhanda Brockington DNP FNP-BC, Andrew Buelt DO, Vincent Capaldi MD MSc FAPA FACP, et al.
Omega-3 Fatty Acid Supplementation for Depression in Children and Adolescents. The Cochrane Database of Systematic Reviews. 2024. Campisi SC, Zasowski C, Bradley-Ridout G, et al.
Nutrition and Prevention of Cognitive Impairment. The Lancet. Neurology. 2018. Scarmeas N, Anastasiou CA, Yannakoulia M.
Omega-3 Fatty Acids for Depression in Adults. The Cochrane Database of Systematic Reviews. 2021. Appleton KM, Voyias PD, Sallis HM, et al.
Omega-3 Polyunsaturated Fatty Acids Suppress the Inflammatory Responses of Lipopolysaccharide-Stimulated Mouse Microglia by Activating SIRT1 Pathways. Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids. 2017. Inoue T, Tanaka M, Masuda S, et al.
Immunomodulation of Microglia by Docosahexaenoic Acid and Eicosapentaenoic Acid. Current Opinion in Clinical Nutrition and Metabolic Care. 2012. Hjorth E, Freund-Levi Y.
Impairment of DHA Synthesis Alters the Expression of Neuronal Plasticity Markers and the Brain Inflammatory Status in Mice. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2020. Talamonti E, Sasso V, To H, et al.
Experimental Evidence of ω ‐3 Polyunsaturated Fatty Acid Modulation of Inflammatory Cytokines and Bioactive Lipid Mediators: Their Potential Role in Inflammatory, Neurodegenerative, and Neoplastic Diseases. BioMed Research International. 2013. Calviello G, Su HM, Weylandt KH, et al.
Omega-3 Fatty Acids and Cognitive Function. Current Opinion in Lipidology. 2023. Welty FK.